Deciphering the complexities of inflammasome activation following RSV infection
破译 RSV 感染后炎症小体激活的复杂性
基本信息
- 批准号:10807884
- 负责人:
- 金额:$ 38.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Abstract
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in children, the elderly and
immunocompromised individuals and there is currently no licensed RSV vaccine. The host inflammatory
response is believed to contribute to disease severity following RSV infection. Much less is currently known
regarding the role of RSV strains in modulating the host inflammatory response. The production of
proinflammatory cytokines IL-1β and IL-6 have been found to be significantly increased in the respiratory tract
of infants with severe disease. In addition, RSV infection has been reported to promote hypermetabolism in the
upper respiratory cells of RSV-infected children. IL-1β is a key proinflammatory cytokine and its secretion is
tightly regulated by multi-protein complexes named inflammasomes. Activation of the inflammasome is a two-
step process, including priming and activation steps, that requires metabolic reprogramming of the cell.
Previous studies have demonstrated that RSV A2 infection induces the activation of the NLRP3
inflammasome. Our preliminary data illustrate that infection with the RSV 2-20 strain results in significantly
increased IL-1β production as compared to infection with the A2 strain. We also observe an increase in
glycolysis in RSV 2-20 infected macrophages as compared to A2 infected macrophages. Unexpectedly, when
we infect cells with a recombinant RSV A2 strain engineered to express the 2-20 fusion (F) protein, termed
A2/2-20F, we observe a significant increase in both IL-1β production and glycolysis in macrophages. Thus, our
exciting new preliminary data indicate that RSV strains differentially activate the inflammasome and this strain-
dependent increased inflammasome activation is mediated by the F protein. Thus, important knowledge gaps
exist regarding how RSV-derived genes modulate the host inflammatory response. Our long-term goal is to
understand the virus-derived factors that modulate the host immune response and disease severity following
RSV infection. The objective of this application is to determine the changes that occur in inflammasome
signaling and metabolism following RSV infection. Moreover, we will explore how these changes impact innate
cell recruitment into the lung and shape the subsequent adaptive immune response. Our central hypothesis is
that the RSV 2-20 strain enhances both inflammasome priming and activation signals resulting in increases in
both neutrophil influx and the Th17 response. We will achieve the goals outlined above by pursuing the
following two specific aims: Aim 1. Determine the mechanism of RSV F protein-mediated inflammasome
activation. Aim 2. Examine the role of differential inflammasome activation on immune cell recruitment and
disease following RSV infection. The knowledge gained from these studies will provide a mechanistic
understanding of RSV-mediated inflammatory responses. In addition, these studies will greatly impact the
evaluation of therapeutic targets and design of future RSV vaccine candidates.
摘要
呼吸道合胞病毒(RSV)是儿童、老年人和
在某些实施方案中,RSV疫苗用于免疫功能低下的个体,并且目前没有许可的RSV疫苗。宿主炎症
RSV感染后,应答被认为有助于疾病的严重程度。目前所知的要少得多
关于RSV株在调节宿主炎症反应中的作用。生产
已经发现促炎细胞因子IL-1β和IL-6在呼吸道中显著增加
患有严重疾病的婴儿。此外,据报道RSV感染可促进糖尿病患者的高代谢。
RSV感染儿童的上呼吸道细胞。IL-1β是一种关键的促炎细胞因子,其分泌是
由称为炎性小体的多蛋白复合物紧密调控。炎性小体的激活是一个两-
步骤过程,包括引发和活化步骤,其需要细胞的代谢重编程。
先前的研究已经证明,RSV A2感染诱导NLRP 3的活化,
炎性小体我们的初步数据表明,感染RSV 2-20株导致显著的
与用A2菌株感染相比,IL-1β产生增加。我们还观察到,
与A2感染的巨噬细胞相比,RSV 2-20感染的巨噬细胞中的糖酵解。没想到等
我们用重组RSV A2株感染细胞,该重组RSV A2株被工程化以表达2-20融合(F)蛋白,称为
A2/2- 20 F,我们观察到巨噬细胞中IL-1β产生和糖酵解的显著增加。所以我们
令人兴奋的新的初步数据表明,RSV株不同地激活炎性小体,并且该株-
依赖性增加的炎性小体活化由F蛋白介导。因此,重要的知识差距
存在关于RSV衍生基因如何调节宿主炎症反应的问题。我们的长期目标是
了解病毒衍生的因素,调节宿主的免疫反应和疾病的严重程度,
RSV感染。本申请的目的是确定炎性小体中发生的变化,
RSV感染后的信号传导和代谢。此外,我们将探讨这些变化如何影响先天性
细胞募集到肺中并形成随后的适应性免疫应答。我们的核心假设是
RSV 2-20株增强炎性小体引发和激活信号,导致RSV 2-20的表达增加。
中性粒细胞流入和Th 17应答。我们将通过以下方式实现上述目标:
具体目标有两个:目标1。RSV F蛋白介导炎性小体的机制探讨
activation.目标2.检查差异性炎性小体激活对免疫细胞募集的作用,
RSV感染后的疾病。从这些研究中获得的知识将提供一个机械的
了解RSV介导的炎症反应。此外,这些研究将极大地影响
治疗靶点的评估和未来RSV疫苗候选物的设计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven M Varga其他文献
Steven M Varga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven M Varga', 18)}}的其他基金
Deciphering the complexities of inflammasome activation following RSV infection
破译 RSV 感染后炎症小体激活的复杂性
- 批准号:
10655297 - 财政年份:2022
- 资助金额:
$ 38.99万 - 项目类别:
Deciphering the complexities of inflammasome activation following RSV infection
破译 RSV 感染后炎症小体激活的复杂性
- 批准号:
10388682 - 财政年份:2022
- 资助金额:
$ 38.99万 - 项目类别:
Balancing protection versus immunopathology by RSV-specific memory CD8 T cells
RSV 特异性记忆 CD8 T 细胞平衡保护与免疫病理学
- 批准号:
9977905 - 财政年份:2017
- 资助金额:
$ 38.99万 - 项目类别:
Immunopathology mediated by RSV-specific CD4 T cells
RSV 特异性 CD4 T 细胞介导的免疫病理学
- 批准号:
7895292 - 财政年份:2009
- 资助金额:
$ 38.99万 - 项目类别:
Immunopathology mediated by RSV-specific CD4 T cells
RSV 特异性 CD4 T 细胞介导的免疫病理学
- 批准号:
7568970 - 财政年份:2007
- 资助金额:
$ 38.99万 - 项目类别:
Immunopathology mediated by RSV-specific CD4 T cells
RSV 特异性 CD4 T 细胞介导的免疫病理学
- 批准号:
8013503 - 财政年份:2007
- 资助金额:
$ 38.99万 - 项目类别:
Immunopathology mediated by RSV-specific CD4 T cells
RSV 特异性 CD4 T 细胞介导的免疫病理学
- 批准号:
7758806 - 财政年份:2007
- 资助金额:
$ 38.99万 - 项目类别:
相似海外基金
REU Site: Cellular and Molecular Biology of Stress (CMBS): Exploring the Complexities of Adaptation and Resilience
REU 网站:压力细胞和分子生物学 (CMBS):探索适应和恢复力的复杂性
- 批准号:
2349028 - 财政年份:2024
- 资助金额:
$ 38.99万 - 项目类别:
Standard Grant
2DSPEC - Simulating two-dimensional electronic spectroscopy: Capturing the complexities of photo-induced excitedstate molecular processes
2DSPEC - 模拟二维电子光谱:捕获光诱导激发态分子过程的复杂性
- 批准号:
EP/Y037383/1 - 财政年份:2024
- 资助金额:
$ 38.99万 - 项目类别:
Fellowship
AF: Small: Verification Complexities of Self-Assembly Systems
AF:小:自组装系统的验证复杂性
- 批准号:
2329918 - 财政年份:2024
- 资助金额:
$ 38.99万 - 项目类别:
Standard Grant
Cultivating Care-full Practices and Policies: The Prefigurative Possibilities and Complexities of Urban Community Gardens
培育谨慎的实践和政策:城市社区花园的象征性可能性和复杂性
- 批准号:
2888454 - 财政年份:2023
- 资助金额:
$ 38.99万 - 项目类别:
Studentship
Interdisciplinary perspectives on oral and facial pain and headache: unravelling the complexities for improved understanding, prevention, and management
关于口腔和面部疼痛和头痛的跨学科视角:揭示改善理解、预防和管理的复杂性
- 批准号:
487930 - 财政年份:2023
- 资助金额:
$ 38.99万 - 项目类别:
Miscellaneous Programs
Capturing the complexities of informal caregiver networks: New measures to improve outcomes for informal care partners of people living with Alzheimer’s disease and related dementias (AD/ADRD)
了解非正式护理人员网络的复杂性:改善阿尔茨海默病和相关痴呆症 (AD/ADRD) 患者的非正式护理伙伴的结果的新措施
- 批准号:
10728350 - 财政年份:2023
- 资助金额:
$ 38.99万 - 项目类别:
Why the Folate Controversy Persists: The Biosocial Complexities of Folate
为什么叶酸争议持续存在:叶酸的生物社会复杂性
- 批准号:
ES/W010607/2 - 财政年份:2023
- 资助金额:
$ 38.99万 - 项目类别:
Research Grant
Developing Statistical Methods on Event History Data Subject to Data Complexities for HIV Disease Progression and Policy Evaluation
根据艾滋病毒疾病进展和政策评估的数据复杂性,开发事件历史数据的统计方法
- 批准号:
10700452 - 财政年份:2023
- 资助金额:
$ 38.99万 - 项目类别:
CAREER: Scaling Complexities in Soil Biogeochemistry
职业:土壤生物地球化学的复杂性
- 批准号:
2142483 - 财政年份:2022
- 资助金额:
$ 38.99万 - 项目类别:
Continuing Grant
Real-world complexities in opioid use disorder treatment: understanding family comorbidity, high-risk medication use, and costs related to treatment adherence and health outcomes
阿片类药物使用障碍治疗的现实复杂性:了解家庭合并症、高风险药物使用以及与治疗依从性和健康结果相关的成本
- 批准号:
10449784 - 财政年份:2022
- 资助金额:
$ 38.99万 - 项目类别: